PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS DILTIAZEM IN PATIENTS WITH ATRIAL-FIBRILLATION OR ATRIAL-FLUTTER

Article

关键词: ORAL DILTIAZEM;    HEART-RATE;    EFFICACY;    HYPERTENSION;    MULTICENTER;    EXERCISE;    INFUSION;    SAFETY;    REST;   

DOI  :  10.1161/01.CIR.86.5.1421

来源: SCIE

【 摘 要 】

Background. Diltiazem, a calcium channel blocker, has been shown to be safe and effective in the treatment of patients in atrial fibrillation and/or atrial flutter. However, there have been no pharmacokinetic/pharmacodynamic studies of diltiazem in these patients. Methods and Results. The pharmacokinetics and pharmacodynamics of intravenous diltiazem were determined in 32 patients with atrial fibrillation or atrial flutter (mean+/-SD age, 66+/-7 years; mean baseline heart rate, 131+/-10 beats per minute) after 20 mg or 20 mg followed by 25-mg bolus doses and a 10 and 15 mg/hr infusion for 24 hours. After the 10 and 15 mg/hr infusions of diltiazem, mean+/-SD elimination half-life was 6.8+/-1.8 and 6.9+/-1.5 hours, volume of distribution was 411+/-151.8 and 299+/-70.8 1, and systemic clearance was 42+/-12.4 and 31+/-8.3 1/hr, respectively. Percentages of the plasma concentrations of the principal metabolites desacetyldiltiazem and N-desmethyldiltiazem to diltiazem were <15% and <10%, respectively. Thirty of 32 patients maintained response throughout the 24-hour infusion of diltiazem. Using a sigmoidal E(max) pharmacodynamic model, a strong relation (mean+/-SD r2, 0.78+/-0.2) was observed between plasma diltiazem concentration and percent heart rate reduction. Mean+/-SD E. (maximum percent reduction in heart rate from baseline) and EC50 (plasma diltiazem concentration that achieves half E(max)) were 52+/-17% and 110+/-84 ng/ml, respectively. The model predicts that mean plasma diltiazem concentration of 79, 172, and 294 ng/ml are required to produce a 20%, 30%, and 40% reduction in heart rate, respectively. A relation between plasma diltiazem concentration and percent change in systolic blood pressure (SBP) or diastolic blood pressure (DBP) from baseline was not observed (mean+/-SD r2, SBP/DBP: 0.35+/-0.24/0.36+/-0.2). There were no untoward side effects observed. Conclusions. First, the pharmacokinetics of diliazem in patients with atrial fibrillation or atrial flutter is nonlinear with an apparent dose-dependent decrease in systemic clearance with increasing infusion rate. Second, using a sigmoidal E(max) model, there is a strong relation between plasma diltiazem concentration and percent heart rate reduction. Third, the plasma concentrations of the principal metabolites desacetyldiltiazem and N-desmethyldiltiazem are low and are not expected to contribute significantly to the pharmacodynamics of intravenous diltiazem in these patients.

【 授权许可】

Free